Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.90 7.50 8.30 7.90 7.90 7.90 169,500 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.0 -1.5 -0.5 - 30

Eden Research Share Discussion Threads

Showing 9526 to 9550 of 9825 messages
Chat Pages: 393  392  391  390  389  388  387  386  385  384  383  382  Older
DateSubjectAuthorDiscuss
04/9/2020
09:54
As Investing accurately predicted.. News UK organic food and drink sales boom during lockdown Bananas, chicken, eggs and wine the standouts as growth reaches highest rate since 2016 hTTps://www.theguardian.com/environment/2020/sep/03/uk-organic-food-and-drink-sales-boom-during-lockdown
supersonico
04/9/2020
09:00
So he hopes for some sales in Greece does he. Inspiring man is our Sean : he will go far!
chrischas
04/9/2020
08:53
TPI Thanks for posting the link. This was a well produced and delivered film. I never did any film work for Xcite Energy Companies/management are responsible for corporate success, not third parties. Communication is the means by which the corporate story is told and is relevant at the time and I did that well with the information provided and available at the time. The corporate journey can change over time, Eden's has not been great historically, but currently seems immeasurably better, thankfully.
investingisatrickygame
04/9/2020
06:35
''they have to have concrete information delivered so as to be able to understand Company value, per share value at any given time in order to a) make an investment decision & b) whether to retain an investment proposition or add or subtract from this position. Eden has had long enough to understand this, yet as we expect and hope that RNS news flow will now build on these approvals, Eden continues to omit vital information to enable investors to make investment decisions and as such, you have a stale share price. Eden simply doesn't knit this information together and deliver in a cohesive manner for a better position for all shareholders. Come on Eden, please deliver the next RNS correctly and back it up with a more in-depth piece with Proactive Investors on film so that it can be understood by the many'' 10 years on and still bleating on about shoddy PR I see 🤣 sounds all too familiar huh 🤦‍♂;️ https://www.youtube.com/watch?v=3CfFF6Ixe74 ''In my opinion, Eden needs to: 1) Present itself differently 2) Understand its audience, what they are looking for and what they need to hear 3) Reach out that understanding and match their communication to reach this audience 4) Be more buoyant about the prospects within the realms of what they know today 5) Sell their potential prospects for the next year, 2 and 3 6) Explain Eden properly and make sure the listening, reading and watching audience understands Eden properly IF Eden did this properly, we would not be sat at 7p, we would be many multiples higher and the benefit of that would be happier shareholders'' improved communication huh 👀 hmmm shareholders really should be careful what you wish for 😉 https://www.youtube.com/watch?v=lq_azTRZhgc BTW I must admit I had a little chuckle at your oil company analogy Paul given that I know Xcite Energy & New World Oil would have been quite influential when making that rather amateur half hour analogy 🙈 IIATG - working with you but more importantly FOR YOU - tra-la-la-la-la 🤡
the patriotic irishman
03/9/2020
19:44
Unmentionable News Really poor waste of everyone's time Proactive interview where unmentionable characteristically does not mention Headlice or Corteva... WTF hTTps://www.youtube.com/watch?v=tL5s6vTWYQQ&feature=emb_logo
supersonico
03/9/2020
16:52
At the present time 'Back to school' and 'Global market size' have the same value. Zero
supersonico
03/9/2020
16:15
Citing global market size is intended to imply the breadth of Eden’s market. Otherwise, it would have no relevance.
erinvale
03/9/2020
15:13
Erinvale, I disagree. They offer up global market sizes, not their specific market opportunity.
investingisatrickygame
03/9/2020
14:30
Investing: EDEN has been telling the market for years of its product market size and potential. During the same period the share price continues, with the occasional uptick, to decline. Having huge potential is no use without the stimulus of sales Viagra.
erinvale
02/9/2020
18:52
Could it be that they are quite happy with this money spinner over their career lifetime?
chrischas
02/9/2020
15:26
It's taken years of pressure but my docs now onboard as he sees the frustration..
bjlk
02/9/2020
15:26
Well let's hear about any sales of note, let alone increasing sales in a market already approved...
bjlk
02/9/2020
14:37
Spain RNS hxxps://polaris.brighterir.com/public/eden_research/news/rns/story/w68d69r "Eden's product, Cedroz, will play a role in solving the issue of large crop losses due to nematode infestation, which globally cost the agriculture industry $80-100 billion each year. Many vegetable species are affected by nematodes and as a result, the use of nematicides on vegetable crops accounts for over 33% of global nematicide sales" MY COMMENT: I do wish Eden would get away from these global numbers which means nothing to Eden and its shareholders. Eden has been quoting these for many years now. Eden's potential market share and associated sales and the global waste values are so disconnected so as to have no meaning at all. I'd have liked Eden to have said and say on all subsequent country approvals that the market for Nematicides in Spain is worth X, the market for Cedroz in Spain is worth Y and jointly, Eden and Eastman over time hope to penetrate Z value/share. This will give shareholders a sense of true direction and true value for the product that Eden has created and found a distributor for. The rest is meaningless. From the Placing RNS hxxps://polaris.brighterir.com/public/eden_research/news/rns/story/r7n0yvw Spain €14.4 million On reflection from the Placing RNS of the 28th of February 2020, is it saying that the market for Cedroz in Spain is €14.4 million? If so, what is Eden's share? AND, if it is saying Cedroz in Spain carries a potential market value of €14.4 million why has Eden not made mention of this in this weeks approval RNS and padded it out a bit more? Shareholders can buy into a Company's potential They can get excited about a Company's potential They can be patient with the Company They can trust Management BUT, they have to have concrete information delivered so as to be able to understand Company value, per share value at any given time in order to a) make an investment decision & b) whether to retain an investment proposition or add or subtract from this position. Eden has had long enough to understand this, yet as we expect and hope that RNS newsflow will now build on these approvals, Eden continues to omit vital information to enable investors to make investment decisions and as such, you have a stale share price. Eden simply doesn't knit this information together and deliver in a cohesive manner for a better position for sll shareholders. Share value doesn't have to 'out', its not inevitable....one day. Eden has to show value, explain value, ensure value is understood and gauge their success in this capacity by the upward trajectory of the share price and the share register. Come on Eden, please deliver the next RNS correctly and back it up with a more in-depth piece with Proactive Investors on film so that it can be understood by the many. And whatever we do in positive RNS's and subsequent film, please give shareholders reason to buy this stock. That's totally acceptable in your regulatory framework.
investingisatrickygame
01/9/2020
07:55
Anyone else looked at the competition out there? Marones 'Majestene' appears to be the most obvious, not easy to find a break down of sales since it was approved 4 or 5 years ago. hTTps://www.globenewswire.com/news-release/2015/10/08/774584/10152031/en/Marrone-Bio-Innovations-Receives-EPA-Approval-for-MAJESTENE-TM-Bionematicide.html
33mick
01/9/2020
07:55
hTTps://vscnews.com/root-knot-nematode-update/ There doesn't appear to be much in the way of bio nemicide products available at present, maybe one or two I've seen? So maybe Cedroz has a head start here...he says hopefully.... Guessing quite a few in the development phase tho' interesting audio interview at the end, to understand the market here Eden are targeting with Cedroz.
33mick
01/9/2020
07:26
Clarity is very important and will help with Eden's credibility deficit as those Kids going back to Skool will tell you. Unless opacity is the company policy.
supersonico
01/9/2020
07:09
Super, I agree. I'd like Sean to add to each approval that the first shipment of X to the value of y will now be made to z. It just adds clarity and affirms an immediate sales position.
investingisatrickygame
01/9/2020
07:09
Bjlk, Does your GP prescribe medically induced coma ? ;)
supersonico
01/9/2020
07:08
Bjik, Give it a break. They can't sell product pre-approval. Judge initial sales for Spain in 6 months.
investingisatrickygame
01/9/2020
07:04
Wake me up when there any sales, sorry to mention the s word... or possibly wake me up when Shaun builds an extension with profit related pay to house all these approvals
bjlk
01/9/2020
06:36
Agreed G8, I have no problem with the way Eastman/Eden are rolling out Cedroz but I'd like to be told explicitly by Eden on every related RNS if the product is on trial or on sale etc.
supersonico
01/9/2020
06:23
There is a difference between a salesman saying: Buy my new product it is fantastic and will kill the little blighters and make you loads of money, and: My product is fantastic and it will make you loads of money; just look at Juan Carlos down the road who tried it last year and his yields went up by 10.35% and he could sell his tomatoes at a 5.28% premium because they were better quality. Message him to check what he says about Cedroz, he's currently on a month long break in Barbados paid for from his extra profit.
grahamg8
01/9/2020
06:07
Regulatory approval for CedrozT in Spain hTTps://www.investegate.co.uk/eden-research-plc--eden-/rns/regulatory-approval-for-cedrozt-in-spain/202009010700095110X/ A step forward but no info on whether this will be a pre launch trial region by Eastman or actually on sale. This needs to be stated clearly either way imo so we know if it's Jam tomorrow or inthecomingshortorder. From the Mexico approval RNS; Eastman will now embark on a roll-out of Cedroz in the coming year, which includes extensive live trials under local conditions to determine the best possible use of Cedroz in different scenarios and for a range of crops. Experience has shown that an extensive and controlled trial period is essential to the success of such a product launch."
supersonico
31/8/2020
16:08
For those on the science park. Glyphosate and Autism. hTTps://www.youtube.com/watch?time_continue=3&v=fM1iID1ter8&feature=emb_logo Phase out Epidemic ??
supersonico
30/8/2020
17:32
So The '2 years ago' question is.. Will Unmentionable, Shortorder and SwedishNoir manage to herd the parallel channel ecocidal behemoth cats and TT distribution contracts to deliver a solution to an epidemic this September? Or will they continue their stellar reputation of serially disappointing retail shareholders while letting the right ones in ? ........................................... 10 October 2018 TerpeneTech granted regulatory clearance for head-lice product Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its associate company, TerpeneTech Limited ("TerpeneTech"), has received regulatory clearance to sell its head-lice product in the European Economic Area ("EEA"). Sales of the head-lice product into the distribution channel are expected to begin before the end of 2018 in the UK, where TerpeneTech's distribution channel partner has already been established, with commercial launch at the beginning of 2019. Sales will commence in other countries in the EEA once arrangements with additional distribution partners have been finalised. This is expected to take place during 2019. hTTps://polaris.brighterir.com/public/eden_research/news/rns/story/w05v2lr
supersonico
Chat Pages: 393  392  391  390  389  388  387  386  385  384  383  382  Older
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201124 21:00:07